Clinical efficacy of magnesium isoglycyrrhizinate in treatment of liver injury among patients with obstructive jaundice after percutaneous transhepatic cholangiodrainage

Objective To evaluate the clinical efficacy and safety of magnesium isoglycyrrhizinate in the treatment of liver injury among patients with obstructive jaundice after percutaneous transhepatic cholangiodrainage ( PTCD) . Methods Sixty- two obstructive jaundice patients with liver injury after PTCD were randomly divided into treatment group ( n = 32) and control group ( n = 30) . All patients were given vitamin B6, vitamin C, and coenzyme complex by intravenous drip. At the same time, the treatment group was given magnesium isoglycyrrhizinate ( 100 mg) after PTCD for 7 days, while the control group was given reduced glutathione ( 1200 mg) for 7 days. After treatment, the improvements in serum alanine transaminase ( ALT) , aspartate aminotransferase ( AST) , albumin ( Alb) , γ- glutamyl transpeptidase ( GGT) , alkaline phosphatase ( ALP) , total bilirubin ( TBil) , direct bilirubin ( DBil) , tumor necrosis factor- α ( TNFα) , and nuclear factor- kappa B ( NF- κB) were evaluated. The adverse reactions associated with magnesium isoglycyrrhizinate were observed. Results After treatment, both groups showed significant decreases in serum TBil, DBil, ALT, AST, ALP, TNFα, and NF- κB ( P < 0. 05) , and the treatment group had significantly higher decreases in these indices ( P < 0. 05) . However, there were no significant improvements in Alb and GGT in either group after treatment, and the two indices showed no significant differences between the two groups ( P > 0. 05) . Conclusion Treated with magnesium isoglycyrrhizinate, obstructive jaundice patients with liver injury after PTCD can regain the liver function and recover from jaundice rapidly, and magnesium isoglycyrrhizinate has good efficacy and safety.